Navigation Links
Immunosyn Announces Interview of CEO Stephen D. Ferrone by 'CEOCFO Interviews & News'
Date:1/31/2008

LA JOLLA, Calif., Jan. 31 /PRNewswire-FirstCall/ -- Stephen D. Ferrone, CEO and President of Immunosyn Corporation (OTC Bulletin Board: IMYN) has been featured in an exclusive interview with CEOCFO Interviews & News. The interview is posted on http://www.immunosyn.com/news-conferences.html

The interview covers topics including Immunosyn's immediate focus, its future development and its market potential, the shift in the pharmaceutical industry toward biologically-derived drugs, the science behind SF-1019, the role of Argyll Biotechnologies, LLC its strategic partner and largest shareholder, Immunosyn's financial picture, the US and European regulatory approval process as it pertains to SF-1019 trials and milestones for which the public and investors should watch.

"We are pleased to be included with CEOCFO's esteemed collection of companies. This interview offers us the opportunity to present noteworthy announcements to brokers, institutional managers and individual investors as part of our strategic market communication plan," says Stephen D. Ferrone.

About CEOCFO Interviews & News http://ceocfointerviews.com:

CEOCFO Interviews & News is a bi-weekly print online publication, marketing engine featuring publicly traded & venture capital companies on the U.S. (NYSE, NASDAQ, AMEX, OTC: BB, Pink Sheets) and Canadian (TSX & TSX-V) stock exchanges, Investment & Money Management Ideas.

About Immunosyn Corporation

La Jolla, CA-headquartered Immunosyn Corporation (IMYN.OTC.BB) plans to market and distribute life enhancing therapeutics. Currently, the company has exclusive worldwide rights from its largest shareholder, Argyll Biotechnologies, LLC, to market, sell and distribute SF-1019, a compound that was developed from extensive research into Biological Response Modifiers (BRMs). Argyll Biotechnologies, LLC has initiated the process for regulatory approval of SF-1019 in several countries and preparations for clinical trials are underway in both the US and Europe. Research suggests that SF-1019 has the potential to affect a number of clinical conditions including complications from Diabetic Mellitus such as Diabetic Neuropathy (DN) and diabetic ulcers (DU), auto-immune disorders such as Multiple Sclerosis (MS) and neurological disorders such as Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Reflex Sympathetic Dystrophy Syndrome (RSD or RSDS).

The above news release contains forward-looking statements. These statements are based on assumptions that management believes are reasonable based on currently available information, and include statements regarding the intent, belief or current expectations of the Company and its management. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance, and are subject to a wide range of business risks, external factors and uncertainties. Actual results may differ materially from those indicated by such forward-looking statements. For additional information, please consult the Company's most recent public filings and Annual Report on Form 10-K for its most recent fiscal year. The Company assumes no obligation to update the information contained in this press release, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Immunosyn Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Immunosyn Corporation to Present at FSX
2. Immunosyn Corporation Names G. David Criner as CFO
3. WallSt.net Announces Upcoming Interview With CEO Of Immunosyn Corporation
4. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
5. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
6. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
7. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
8. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
9. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
10. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
11. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2016)... ... ... Kablooe Design, a leading provider of product design and development services to ... business. “We have worked hard to build long-term relationships,” says President and CEO, Tom ... of serving their product design and development needs through the years.” , Kablooe has ...
(Date:5/19/2016)... , May 19, 2016 ... will fully recover given the relentless pressures in pricing ... sure in the investors circle though - numerous opportunities ... Ahead of today,s session, ActiveWallSt.com,s presents four names in ... ), Vitae Pharmaceuticals Inc. (NASDAQ: VTAE ), ...
(Date:5/18/2016)... ... May 18, 2016 , ... Shimadzu ... at The University of Toledo. This two-day camp will take place annually starting ... the field of pharmaceutical sciences in preparation for a university academic program. ...
(Date:5/18/2016)... (PRWEB) , ... May 18, 2016 , ... Ryan Benton ... a life expectancy in the late teens to early twenties. DMD is a relatively ... 2009, at the age of 22, Benton’s condition was critical. He met with the ...
Breaking Biology Technology:
(Date:3/31/2016)... Florida , March 31, 2016 ... ) ("LegacyXChange" or the "Company") LegacyXChange ... potential users of its soon to be launched online ... ( https://www.youtube.com/channel/UCyTLBzmZogV1y2D6bDkBX5g ) will also provide potential ... use of DNA technology to an industry that is ...
(Date:3/29/2016)... RATON, Florida , March 29, 2016 ... or the "Company") LegacyXChange "LEGX" and SelectaDNA/CSI Protect are ... DNA in ink used in a variety of writing ... theft. Buyers of originally created collectibles from athletes on ... through forensic analysis of the DNA. ...
(Date:3/22/2016)... India , March 22, 2016 /PRNewswire/ ... market research report "Electronic Sensors Market for Consumer ... Proximity, & Others), Application (Communication & IT, ... Geography - Global Forecast to 2022", published ... industry is expected to reach USD 26.76 ...
Breaking Biology News(10 mins):